Abstract: A cloud based pulse oximetry system and method is provided that incorporates both a software and hardware component. The hardware component includes a limited use pulse oximetry probe having an energy source and data transmitting capabilities. The probe houses a light source and a light detector that compare and calculate the differences in the oxygen-rich versus oxygen-poor hemoglobin in the body part to which, it is attached. Data from the probe is collected, analyzed, and communicated using a cloud based computing system. The system may be used for collecting and analyzing pulse oximetry data for any medical need such as diagnosis of obstructive sleep apnea.
Type:
Application
Filed:
September 19, 2016
Publication date:
May 28, 2020
Applicant:
Serenium, Inc.
Inventors:
David Gozal, David Rosen, Michael Cory Zwerling
Abstract: One aspect of the present invention is to assess the performance of automated analysis of blood oxygen saturation (SpO2) recordings as a screening tool for OSAHS. As an initial step, statistical, spectral and nonlinear features are estimated to compose an initial feature set. Then, a fast correlation-based filter (FCBF) is next applied to search for the optimum subset. Finally, the discrimination power (OSAHS negative vs. OSAHS positive) of three pattern recognition algorithms is assessed: linear discriminant analysis (LDA), quadratic discriminant analysis (QDA) and logistic regression (LR). According to another aspect of the invention, oximetry is used to determine the OSAHS severity in children. For testing the severity of OSAHS, first spectral analysis is conducted to define and characterize a frequency band of interest in SpO2.
Abstract: It was determined that plasma-derived exosomes from either obese (OB) or obstructive sleep apnea (OSA) children with evidence of endothelial dysfunction (ED). Such ED exosomes lead to up-regulation of adhesion molecules in endothelial cells. Exosomal miRNA cargo differences underlie the mechanisms accounting for the presence of ED. Specifically, expression of miRNA-630 is reduced in circulating exosomes of either obese or OSA children with ED, and normalizes in OSA children with ED after treatment along with restoration of endothelial function. These findings elucidate a novel role of exosomal miRNA-630 as a putative key mediator of vascular function and a biomarker of cardiovascular disease (CVD) risk in children.